News

Screening Campaigns for Tuberculosis


1 Mar 2010
by Working Group

source: http://www.glsynthesis.com/drug-discovery.html

Drug discovery teams around the world have been actively selecting targets that are likely to be important in killing dormant or very slowly replicating tuberculosis in an effort to shorten the time to cure; for drug sensitive TB, six to nine months treatment time and drug resistant TB, up to two years treatment time. Some of these targets have been processed through high throughput screening (HTS) campaigns comprising millions of compounds but little to no follow up on the hits from these screening campaigns has been reported. Often when a person discusses these targets with the scientists that performed the HTS, the standard response is that these targets are “non-druggable”.

Whether it’s a lousy target, the compound collection screened was or was not the best fit or there was limited bacterial potency in the follow-up bacterial cell assays remains unclear. In an effort to determine what targets have or have not been processed and why, The Stop TB Working Group for New Drugs Biology/Targets Sub-group is seeking to triage the best drug targets. First, we are attempting to understand what has been done to date by different groups through surveys and direct communication.

Out of frustration or a lack of productive results, many scientists are abandoning target based screens in lead optimization efforts in favor of phenotypic screens using whole cell bacteria. However, this approach leaves medicinal chemists working blind with respect to new directions in lead optimization efforts to drive compound potency, and for M. tuberculosis, the question of cell culture media and carbon sources can derail a drug discovery effort due to altered bacterial physiology. Drug screening campaigns that integrate both physiologically-relevant phenotypic screens and target-based efforts may be the middle path and a faster way to generating new drug leads for tuberculosis.

Would you like to get involved? What targets are you working on? What targets have you worked on? What challenges or hurdles did you come across? Please contact the WGND Biology/Targets subgroup with any information that you believe will aid and speed TB drug discovery.

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...